Jingsong Zhang

18PUBLICATIONS
119CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer cell biologyPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|May 25, 2026
Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial.

|May 04, 2026
Myosteatosis and Sarcopenic Obesity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Rationale for Mechanism-Driven Multimodal Intervention.

|Jun 14, 2025
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.

Timothy A Yap, David S P Tan, Anastasios Stathis

|Nov 09, 2024
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.

Roger Li, Nancy Y Villa, Xiaoqing Yu

|Sep 14, 2024
Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies.

Jingsong Zhang, Juskaran S Chadha

|Aug 08, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).

Maha Hussain, Masha Kocherginsky, Neeraj Agarwal

Pageof 3

Frequent Collaborators

3 joint publications

Xuefeng Wang

3 joint publications

Alexander R A Anderson

3 joint publications

Jasreman Dhillon

2 joint publications

Robert Gatenby